CannBioRx Life Sciences Corp (ATNFW)
$0.43
$-0.03
(-6.52%)
As on 15-Aug-2025 16:28EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
8 Years Aggregate
CFO
$-34.61 Mln
EBITDA
$-76.23 Mln
Net Profit
$-121.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CannBioRx Life Sciences Corp (ATNFW)
| 4,474.5 | 5,275.0 | 4,677.8 | 3,956.6 | 44.4 | -- | -- |
|
BSE Sensex*
| -12.3 | -3.4 | -8.6 | -8.8 | 5.8 | 7.4 | 10.8 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
CannBioRx Life Sciences Corp (ATNFW)
| 122.3 | -92.6 |
|
BSE Sensex
| 8.1 | 18.7 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout CannBioRx Life Sciences Corp (ATNFW)
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development... platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California. Read more
-
Co-Founder & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
-
Co-Founder
Sir Marc Feldman Ph.D.
-
Headquarters
Palo Alto, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for CannBioRx Life Sciences Corp (ATNFW)
What is the current share price of CannBioRx Life Sciences Corp (ATNFW) Today?
The share price of CannBioRx Life Sciences Corp (ATNFW) is $0.43 (NASDAQ) as of 15-Aug-2025 16:28 EDT. CannBioRx Life Sciences Corp (ATNFW) has given a return of 44.37% in the last 3 years.
What is the current PB & PE ratio of CannBioRx Life Sciences Corp (ATNFW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
-0.02
|
|
2022
|
0.00
|
0.10
|
|
2021
|
0.00
|
0.16
|
|
2020
|
-0.17
|
0.06
|
What is the 52 Week High and Low of CannBioRx Life Sciences Corp (ATNFW)?
The 52-week high and low of CannBioRx Life Sciences Corp (ATNFW) are Rs 0.62 and Rs 0.00 as of 01-Jun-2026.
What is the market cap of CannBioRx Life Sciences Corp (ATNFW)?
CannBioRx Life Sciences Corp (ATNFW) has a market capitalisation of $ 251 Mln as on 15-Aug-2025. As per SEBI classification, it is a company.
Should I invest in CannBioRx Life Sciences Corp (ATNFW)?
Before investing in CannBioRx Life Sciences Corp (ATNFW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.